Decree 2026-288 explained: what period underwear buyers and suppliers need to know
How to evaluate period underwear suppliers for Decree 2026-288
“Over more than a decade in this category I have had the privilege of working with category teams, procurement leads and finance directors at some of the most respected retail names in the world. The conversation that comes up most often is the same: the business case looked watertight until the supplier numbers landed. The new French government menstrual equity and waste reduction scheme has created a significant opportunity for participating organisations, but the €19 retail price cap is unforgiving so I wanted to share what I have learned about building a case that actually holds up.”
Outline
-
Why standard purchasing templates do not fit Decree 2026-288
-
Deconstructing the €19 retail price cap for period underwear
-
The pharmacy retail margin and where it lives
-
The four variables behind a defensible business case
-
Modelling network volume against eligible catchment
-
The questions your CFO/DAF will ask before sign-off
-
Where the next stage of work begins
Key takeaways
The French government has set a VAT-inclusive €19 retail price cap for period underwear eligible for its new menstrual equity and waste reduction scheme. Your challenge is finding a supplier whose landed cost of goods can hold that cap without eroding margins or cutting compliance corners or performance standards. Your business case stands or falls on four variables, and three of them sit with your supplier.
- The €19 retail reference price is fixed
- Landed unit cost determines whether margins hold
- Volume reliability turns forecasts from fiction into revenue
- Compliance gaps are binary, not graduated
- Working capital cost belongs in your model
- Catchment demographics weight your network demand
- Downside scenarios are the test of credibility
An introduction
The temptation with any new government-mandated category is to treat the business case as straightforward. The eligible population is published, the retail price is capped and the reimbursement rate is set, so the maths looks like it should be a calculator job.
It is not, for one reason: the VAT-inclusive €19 retail reference price (prix limite de vente) is a ceiling, not a floor. Inside that ceiling sits VAT, your pharmacy retail margin, your distributor margin, your supplier cost of goods landed in France, and the working capital cost of holding national volume stock. If your supplier’s landed cost is too high, the only ways to make the numbers work are to compress margins (commercially unacceptable to the network) or to cut compliance corners (legally and reputationally unacceptable to your brand).
A defensible business case for this scheme is one whose unit economics survive interrogation by your CFO or Directeur Administratif et Financier (DAF), your compliance lead and the pharmacist network that is going to retail the product. This article walks through how to build that case, and what to put in front of the people who have to sign it off.
Why standard purchasing templates do not work for this scheme
Most new product business cases assume some pricing flexibility, some volume flexibility and some launch date flexibility. The French menstrual equity scheme removes all three.
The retail price of washable period underwear eligible for reimbursement is capped by decree at €19. Although still substantial, volumes are bounded by the eligible population (around 6.7 million people made up of under-26s and beneficiaries of the Complémentaire Santé Solidaire or C2S) and the two-product annual limit per individual. Launch date is fixed at the start of the new university term on 1 October 2026, with pharmacy exclusivity until 31 December 2028, which sets a hard competitive window inside which the pharmacy channel needs to establish itself before supermarkets and ecommerce become eligible.
Standard purchasing templates do not handle this combination well. They assume price as a lever, but here there is no lever. They assume volume scales linearly with marketing spend, but here it does not. They assume launch dates can slip, but here missing the October launch would be missing the initial rush of publicity and purchasing. Your template needs to start from the constraints.
Deconstructing the €19 retail price cap for period underwear
Working backwards from €19 minus VAT, the cost stack has to allocate to three buckets:
- Pharmacy retail margin is the first bucket. The French pharmacy margin structure for OTC and parapharmacy categories is regressive and varies by product type and distribution route, but commercial planning for a hygiene category in this segment typically anchors against an assumed pharmacy retail margin loosely in the region of 30% of net selling price. Pin your own assumption with your distributor before locking the model.
- Distributor or wholesaler margin sits between your shipment into France and the pharmacy. The exact rate depends on whether you are routing through a full-line pharmaceutical wholesaler, a buying group or direct-to-pharmacy arrangements. Each route changes the margin and the working capital profile.
- Supplier cost of goods landed in France is what is left. This is the variable that separates suppliers who can deliver a workable business case from suppliers who cannot.
When you populate the stack with realistic assumptions for pharmacy margin and distributor margin, the landed cost of goods envelope that remains is significantly narrower than most purchasing managers and category buyers initially expect. That is the test.
The four variables your business case must address
- Landed unit cost: Can your supplier deliver fully compliant product, with the complete certification stack and verified performance, at a landed cost that holds €19 and protects the pharmacy retail margin you have committed to?
- Volume reliability: With an estimated additional three million units of demand for period underwear per year, the opportunity is sizeable for brands that can deliver national volumes. Can your supplier reliably deliver in time for the 1 October launch? If not, your revenue forecast is fiction.
- Working capital cost: Holding national-volume regulated hygiene stock has a real financing cost. Long supplier lead times amplify it. The cost belongs in the model, not in a footnote.
- Compliance risk-adjusted revenue: If your supplier is missing a single decree-mandated regulatory requirement or technical specification, your product will not get a reimbursement code, your product will not be referenced by the pharmacy ordering system and your revenue line collapses.
Three of those four variables sit with your supplier. That is the structural reason the supplier decision is the business case decision.
Modelling network volume against your eligible catchment
The 6.7 million eligible population is national. Your network sees a segment of it, weighted by pharmacy density in catchments with higher under-26 and C2S concentrations.
A sensible first-pass model takes your share of the national pharmacy footprint, applies it to the widely cited three-million-unit demand estimate for year one, and then weights for catchment demographics. A second-pass model adjusts for adoption curve assumptions (year one penetration is unlikely to be the long-run steady state) and for substitution effects, since reusable menstrual cups are an alternative reimbursable product inside the same scheme and will absorb some of the demand.
Build the model in three scenarios: a conservative case that prices in a slower adoption curve, a base case that assumes the published estimate holds, and an upside case that reflects the protected channel position pharmacies hold until the end of 2028. Show the breakeven volume for each. CFOs/DAFs do not approve point estimates, they approve ranges.
The questions your CFO or DAF will ask before sign-off
A useful test of business case readiness is whether you have clean answers to the following:
- What is our breakeven unit volume in year one?
- What happens to the P&L if our supplier slips delivery by 30 days?
- What compliance risk premium are we applying, and is it credible?
- What happens if our shortlisted supplier fails a certification audit between now and the October 2026 launch?
- What is our contingency if landed cost moves against us between contract signing and first delivery?
If any of those answers is ‘we’re not sure’ that gap needs to be closed before sign-off. The downside cases are the test of how seriously the model has been built.
Next steps: Supplier selection for Decree 2026-288
Once the business case is signed off, the work shifts to supplier selection. The next article in this series sets out a four-filter framework for evaluating suppliers against the demands of the scheme: the certification requirements, independent performance verification, evidence of manufacturing scale, and unit economics that hold the €19 price cap without compressing pharmacy and distributor margins. It also covers the red flags that should disqualify a supplier from your shortlist before contract signing, rather than after launch failure.
Read more on this topic in this five-blog series
About the author
Frantisek Riha-Scott, Founder and CEO, Confitex Technology
As the tech leader in reusable personal hygiene since 2013, Confitex designs and manufactures award-winning washable period and incontinence products for leading retail, pharmacy and healthcare brands worldwide. Frantisek has spent more than a decade working at the intersection of fashion design, textile engineering and absorbent hygiene manufacturing, and has worked directly with independent laboratories to shape emerging industry performance standards for reusable absorbent hygiene. His perspective on the French menstrual equity and waste reduction scheme is grounded in detailed working knowledge of the certifications required to trade under Decree 2026-288 and in active conversations with organisations preparing for the September 2026 launch. He writes to help pharmacy category managers, hygiene buyers, purchasing directors and procurement leaders cut through the regulatory complexity and make supplier decisions with confidence. Connect with Frantisek on LinkedIn.
